reports
Psychemedics Releases 2025 Workforce Insights Report
Psychemedics Releases 2025 Workforce Insights Report Synthetic Drug Threats and Legalization Risks Shape a New Era for Workplace Safety DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk. The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug testing results in the industr...
Psychemedics Named “Most Innovative Drug Testing Company of the Year”
Psychemedics Named “Most Innovative Drug Testing Company of the Year” DALLAS, May 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world’s leading provider of hair drug testing, is proud to announce it has been named “Most Innovative Drug Testing Company of the Year” by Acquisition International Magazine as part of its prestigious 2025 Global Excellence Awards. This recognition honors Psychemedics’ continued leadership in advancing the science of drug detection, including the recent launch of its Enhanced Quartile Reporting. This breakthrough analytics tool provides deeper insi...
Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced D...
Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing Insights DALLAS, March 03, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair drug testing, is proud to announce the launch of its innovative Quartile Reporting feature. This industry-first enhancement empowers organizations with unprecedented insights into drug test results, enabling data-driven decision-making and fostering safer, more productive workplaces. The new Quartile Reporting feature allows clients to see where a candidate’s or employee’s test results fall within a range o...
- Jonathan Moreland
PBF PBF ENERGY INC. CLASS A
NMFC NEW MOUNTAIN FINANCE CORPORATION
HRZN HORIZON TECHNOLOGY FINANCE CORP.
CNC CENTENE CORPORATION
FI FRANK'S INTERNATIONAL NV
PMD PSYCHEMEDICS CORP.
EB EVENTBRITE
DOW DOW INC.
BCYC BICYCLE THERAPEUTICS
OXLC OXFORD LANE CAPITAL CORP.
UAN CVR PARTNERS LP
BIGZ BLACKROCK INNOVATION AND GROWTH TST
SES SES AI CORPORATION
GAM GENERAL DE ALQUILER DE MAQUINARIA
MDRR MEDALIST DIVERSIFIED REIT INC.
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
MYE MYERS INDUSTRIES INC.
MTDR MATADOR RESOURCES COMPANY
LTRX LANTRONIX INC.
HRZN HORIZON TECHNOLOGY FINANCE CORP.
FCN FTI CONSULTING INC.
CVGI COMMERCIAL VEHICLE GROUP INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
MEDP MEDPACE HOLDINGS INC.
AUP AURINIA PHARMACEUTICALS INC.
CULP CULP INC.
PETS PETMED EXPRESS INC.
SCVL SHOE CARNIVAL INC.
TREE LENDINGTREE INC.
PMD PSYCHEMEDICS CORP.
DMLP DORCHESTER MINERALS L.P.
LILA LIBERTY LATIN AMERICA A
HHS HARTE-HANKS INC.
ETST EARTH SCIENCE TECH
TCPC BLACKROCK TCP CAPITAL CORP.
DBI DESIGNER BRANDS INC. CLASS A
ORGO ORGANOGENESIS HOLDINGS (A)
ETNB 89BIO
PCB PACIFIC CITY FINANCIAL CORP
RZLT REZOLUTE
RVMD INC.
SSSS REVOLUTION MEDICINES
FTHM SUTTER ROCK CAPITAL CORP.
GNSS FATHOM HOLDINGS
CTGO GENASYS INC
AGL CONTANGO ORE INC.
NOTV AGILON HEALTH
AUID INC.
TRIN INOTIV
TCBX INC.
IBRX IPSIDY INC.
BIGZ TRINITY CAPITAL INC
MODD THIRD COAST BANCSHARES INC
GRNT IMMUNITYBIO INC
UAMY BLACKROCK INNOVATION AND GROWTH TST
TKO MODULAR MEDICAL INC
SRBK GRANITE RIDGE RESOURCES INC
NCDL U S ANTIMONY CORP
SPRU TKO GROUP HOLDINGS
AVDL INC.
CATX SR BANCORP INC
MRAI NUVEEN CHURCHILL DIRECT LENDING CORP
GWAV SPRUCE POWER HOLDING CORP
AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
PERSPECTIVE THERAPEUTICS
INC.
MARPAI
INC.
GREENWAVE TECHNOLOGY SOLUTIONS INC
- Jonathan Moreland
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
CULP CULP INC.
NSC NORFOLK SOUTHERN CORPORATION
PMD PSYCHEMEDICS CORP.
DMLP DORCHESTER MINERALS L.P.
BBDC BARINGS BDC INC.
DBI DESIGNER BRANDS INC. CLASS A
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
RZLT REZOLUTE
CTGO INC.
NOTV CONTANGO ORE INC.
TRIN INOTIV
IBRX INC.
GRNT TRINITY CAPITAL INC
AVDL IMMUNITYBIO INC
MIO GRANITE RIDGE RESOURCES INC
AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
Psychemedics Corporation Announces Reverse and Forward Stock Split
Psychemedics Corporation Announces Reverse and Forward Stock Split DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq: PMD) (the “Company”), the world’s leading provider of hair testing for drugs of abuse, today announced that, following the approval of the Company’s stockholders at its Annual Meeting of Stockholders held on November 25, 2024, the Company’s Board of Directors has approved a 1-for-5,000 reverse stock split of its common stock (the “Reverse Stock Split”) followed immediately by a 5,000-for-1 forward stock split of its common stock (the “Forward Stock...
Psychemedics Corporation Reminds Stockholders to Cast Their Votes for ...
Psychemedics Corporation Reminds Stockholders to Cast Their Votes for Upcoming Annual Meeting of Stockholders DALLAS, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing, reminds its stockholders to vote ahead of the Company’s upcoming annual meeting of stockholders scheduled for November 25, 2024. Each stockholder’s vote is important. The Company’s Board of Directors recommends that stockholders vote "FOR" each proposal at the annual meeting. Instructions for voting your shares are set forth below. The record date for the annual meet...
Psychemedics Corporation Reports Third Quarter 2024 Financial Results
Psychemedics Corporation Reports Third Quarter 2024 Financial Results DALLAS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ending September 30, 2024. The Company’s revenue for three months ended September 30, 2024, was $5.2 million versus $5.7 million for three months ended September 30, 2023, a decrease of 9%. Net loss was $0.5 million, or $0.09 per share, compared to a net loss of $2.1 million, or $0.36 per share, for the three months end...
Psychemedics Releases First-Ever Education Insights Report: Uncovering...
Psychemedics Releases First-Ever Education Insights Report: Uncovering Drug Trends in Educational Institutions Through Hair Testing DALLAS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, is excited to announce the release of its first-ever Education Insights Report. This report provides an in-depth analysis of drug trends within educational institutions, shedding light on the growing challenges schools face in maintaining a drug-free environment for students and staff. Following the success of our inaugur...
Psychemedics Corporation Launches New Ketamine Hair Testing Service
Psychemedics Corporation Launches New Ketamine Hair Testing Service DALLAS, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing, is proud to announce the launch of its new ketamine hair testing solution. This innovative testing method marks a significant advancement in the detection and prevention for a drug-free workplace and community. Ketamine, a powerful dissociative anesthetic and emerging drug of abuse, poses a growing concern for employers, educators, and law enforcement agencies. With the introduction of this new tes...
Psychemedics Corporation Reports Second Quarter 2024 Financial Results
Psychemedics Corporation Reports Second Quarter 2024 Financial Results DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the second quarter ending June 30, 2024. The Company’s revenue for three months ended June 30, 2024, was $4.7 million versus $5.5 million for three months ended June 30, 2023, a decrease of 15%. Net loss was $0.8 million, or $0.14 per share, compared to a net loss of $0.7 million, or $0.13 per share, for the three months ended June 2024...
Psychemedics Corporation’s Board of Directors Approves Plan to Termina...
Psychemedics Corporation’s Board of Directors Approves Plan to Terminate Registration of Its Common Stock DALLAS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) (“Psychemedics” or the “Company”) today announced that a Transaction Committee (the “Transaction Committee”) of the Board of Directors of the Company (the “Board”) comprised of independent directors has recommended, and the Board has approved, a plan to cease the registration of the Company’s common stock under the federal securities laws following the completion of a proposed reverse stock split and to de...
Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends ...
Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a comprehensive analysis of drug trends in the workplace, drawing insights from a vast dataset of hair samples collected and analyzed in 2023. As pioneers in the field of hair testing, Psychemedics collected hundreds of thousands of hair samples from individuals across diverse industrie...
Psychemedics Corporation Reports First Quarter 2024 Financial Results
Psychemedics Corporation Reports First Quarter 2024 Financial Results DALLAS, May 14, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2024. The Company’s revenue for the quarter ended March 31, 2024, was $5.4 million versus $5.9 million for the quarter ended March 31, 2023, a decrease of 9%. Net loss for the quarter was $0.7 million, or $0.12 per share, compared to a net loss of $0.4 million, or $.07 per share, for the comparable quarte...
Psychemedics Corporation Reports 2023 Financial Results
Psychemedics Corporation Reports 2023 Financial Results DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023. “2023 proved to be another challenging year due to the negative impact of major economic forces. The labor shortage continues and remains unprecedented in its severity and duration, having an adverse impact on our clients. Despite these challenges, my confidence in our potential continues to increase. As cost reducti...
Psychemedics Recognized as a Top 10 Employee Health Testing Services P...
Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider Dallas, TX, March 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024 by ManageHR. This prestigious accolade highlights Psychemedics’ commitment to excellence and innovation in the field of employee health testing. ManageHR’s annual list recognizes companies that excel in providing cutting-edge solutions and services for employee heal...
Psychemedics Corporation Announces Relocation of Headquarters to Dalla...
Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, proudly announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to delivering exceptional service and maintaining the highest standards in hair drug testing. The move to Dallas underscores Psychemedics’ commitment to expanding operations, fostering innovation, and better serving its diverse cliente...
Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance
Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she will play a pivotal role in st...
Psychemedics Corporation Reports Third Quarter 2023 Financial Results
Psychemedics Corporation Reports Third Quarter 2023 Financial Results ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company’s revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net loss of $(97,000) or $(0.0...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.